<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166320</url>
  </required_header>
  <id_info>
    <org_study_id>2009/1034-31/3</org_study_id>
    <secondary_id>2009/1034-31/3</secondary_id>
    <nct_id>NCT02166320</nct_id>
  </id_info>
  <brief_title>Treatment of Malignant Strictures in Esophagus and Gastroesophageal Junction With Covered or Partially Covered Stent.</brief_title>
  <acronym>StentMig</acronym>
  <official_title>The Importance of Stent Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blekinge County Council Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Self expandable stent (SEMS) constitutes the main palliative treatment in advanced esophageal
      cancer. The palliative effect of SEMS is immediate when it comes to relief of dysphagia. The
      duration of this effect is however questionable. The design of SEMS can be of importance
      since the device can dislodge and as a consequence of that dysphagia recur. The hypothesis
      has therefore been formulated that a partially covered SEMS is associated with less tendency
      to dislocate as compared to those SEMS, recently developed, which are covered through their
      entire length.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SEMS dislocation in cm during first thirty days after stent insertion.</measure>
    <time_frame>Thirty days from stent deployment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQOL)</measure>
    <time_frame>Within three months of SEMS deployment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for reintervention</measure>
    <time_frame>Within three months after SEMS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of dysphagia within three months of SEMS.</measure>
    <time_frame>Three months after insertion.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Cancer of Gastro Esophageal Junction</condition>
  <condition>Palliative Treatment</condition>
  <arm_group>
    <arm_group_label>Partially covered SEMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Boston Scientific Ultraflex SEMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fully covered SEMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boston Scientific Wallflex Esophageal SEMS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Partially covered SEMS</intervention_name>
    <arm_group_label>Partially covered SEMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fully covered SEMS</intervention_name>
    <arm_group_label>Fully covered SEMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Verified Squamous Cell Carcinoma or Adenocarcinoma of esophagus or Gastro Esophageal
             Junction (GEJ)

          -  Age above 18 years.

          -  Dysphagia scoring grade two or worse

          -  Not amenable for curative treatment

          -  Informed consent to participate

        Exclusion Criteria:

          -  Concomitant cancer disease

          -  Inability to comply with study protocol

          -  Previous stent treatment

          -  Proximal location of the tumour in the esophagus.

          -  Need for more than one stent deployment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Johnsson, MdPhd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Clinic of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magnus Nilsson, ass professor</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erik Johnsson</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Lundell</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

